Cempra, Inc. of New York to Ring The NASDAQ Stock Market Closing Bell in Celebration of Initial Public Offering (IPO)

ADVISORY, Feb. 15, 2012 (GLOBE NEWSWIRE) --

What:

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, will visit the NASDAQ MarketSite in Times Square. Cempra visits in celebration of its initial public offering, which took place on January 3, 2012 on The NASDAQ Global Market under the ticker symbol, "CEMP."

In honor of the occasion, Prabhavathi Fernandes, CEO, will ring the Closing Bell. 

Where:

NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Thursday, February 16th, 2012 – 3:45 p.m. to 4:00 p.m. ET     

Contact:

Elliot Fox

(212)845-4253

Elliot.fox@russopartnersllc.com

NASDAQ MarketSite:

Jen Knapp

(212) 401-8916

Jennifer.knapp@nasdaqomx.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC 3/4

SR 13.235

DR 18.295411

MOD 4:2:0

DVBS QPSK

Facebook and Twitter:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:

http://www.facebook.com/#!/NASDAQ.             

For news tweets, please visit our Twitter page at:

http://twitter.com/nasdaqomx

Webcast:

A live webcast of the NASDAQ Closing Bell will be available at:

http://www.nasdaq.com/about/marketsitetowervideo.asx or http://social.nasdaqomx.com.

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.                          

About Cempra, Inc.:

Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

About NASDAQ OMX:

The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with more than 3,500 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX first North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook (http://www.facebook.com/#!/NASDAQ) and Twitter (http://www.twitter.com/nasdaqomx). 

-NDAQA-

In This Story

NDAQ